Market News & Trends
New Preclinical Data From Encoded Therapeutics Demonstrate Therapeutic Potential of its One-time, Non-opioid Gene Therapy Candidate for Chronic Pain
Encoded Therapeutics Inc. recently announced preclinical data demonstrating that its AAV9 microRNA (miRNA) gene therapy candidate achieved robust knockdown of SCN9A (NaV1.7), a key mediator of…
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics recently announced it has received authorization from the European Medicines Agency (EMA) to initiate the Company’s Phase 2 RENEW clinical trial of its…
Gelteq Announces New Product Development Agreement With Melbourne Health for Novel Bowel Polyp Growth Reduction Compound
Gelteq Limited recently announced it has entered into a Product Development and Profit Share Agreement with Melbourne Health, operator of The Royal Melbourne Hospital and…
Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment
Annovis Bio, Inc. recently announced new results that demonstrate buntanetap’s ability to attenuate inflammation and improve cellular health in Alzheimer’s patients, suggesting potential disease-modifying effects…
Roquette Boosts Extensive Cyclodextrins Portfolio With Launch of KLEPTOSE® Crysmeb methyl-beta-cyclodextrin for Oral & Parenteral Formulations
Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, recently launched of its latest novel pharmaceutical excipient: KLEPTOSE®…
Zenas BioPharma & InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
Zenas BioPharma, Inc. and InnoCare Pharma Limited recently announced a transformational license agreement granting Zenas global development and commercialization rights to orelabrutinib for Multiple Sclerosis…
Owen Mumford Appoints Mark Glass as Director of Pharmaceutical Services
Owen Mumford, a globally recognised innovator in medical device development and manufacturing, has announced the appointment of Mark Glass as Director of Pharmaceutical Services. With a strong scientific…
Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 Into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy Secondary to AMD
Complement Therapeutics GmbH (CTx), a biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared…
Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients With Lower-Risk MDS
Rigel Pharmaceuticals, Inc. recently announced the first patient has been enrolled in the dose expansion phase of the ongoing Phase 1b study of R289 in…
Lisata Therapeutics & Catalent Announce Global Antibody-Drug Conjugate License Agreement
Lisata Therapeutics, Inc. and Catalent, Inc. recently announced a global product license agreement that allows Catalent to incorporate Lisata’s certepetide into antibody-drug conjugates (ADCs) developed…
Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology
Nutriband Inc. recently announced that it has filed a provisional patent application with the US Patent and Trademark Office (USPTO) to further strengthen Nutriband’s intellectual…
NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model
NurExone Biologic Inc. recently announced new preclinical results showing that its lead candidate ExoPTEN produces a reproducible, dose-dependent therapeutic effect in an eye model of glaucoma.…
Salipro Biotech Strengthens Global IP Portfolio With Two New Patents
Salipro Biotech AB recently announced the issuance of two new patents by the Japanese Patent Office. These patents further solidify the company’s intellectual property (IP)…
Resalis Therapeutics Reports Durable, Fat-Selective Weight Loss With RES-010 in Non-Human Primates
Resalis Therapeutics recently presented new preclinical results on its lead candidate RES-010, a first-in-class antisense oligonucleotide targeting microRNA-22 (miR-22). The data was presented at the European…
GLD Partners LP Launches New Biotech Company to Accelerate Drug Discovery for Muscle-Wasting Diseases
GLD Partners LP recently announced the launch of Altagenics, a new biotechnology company leveraging Heligenics’ proprietary GigaAssay platform to accelerate drug discovery. The collaboration will initially…
RheumaGen & SiVEC Biotechnologies Announce CGT Partnership & In Vivo Program to Cure Common Autoimmune Diseases
RheumaGen, Inc. and SiVEC Biotechnologies, Inc. recently announced a licensing and joint development agreement for a breakthrough class of gene-editing therapies designed to cure autoimmune…
Terumo Announces Completion of Acquisition of WuXi Biologics Drug Product Plant in Leverkusen, Germany
Terumo Corporation recently announced the successful completion of its acquisition of a Drug Product Plant and associated Quality Control Laboratory operations from WuXi Biologics in Leverkusen,…
NanoPhoria Bioscience Secures Funding to Advance Breakthrough Heart Failure Therapy & Expand Portfolio for Novel Nano-in-Micro Delivery Platform
NanoPhoria Bioscience recently announced the successful first close of its €83.5 million Series A financing round. The round was led by XGEN Venture, Sofinnova Partners,…
Oculis Accelerates Privosegtor Into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-Class Neuroprotective Therapy
Oculis Holding AG recently announced the advancement of Privosegtor into a registrational program for neuro-ophthalmology indications following a positive meeting with the US FDA. Privosegtor…
Dyadic Applied BioSolutions Announces Milestone Achievements & Recent Company Developments
Dyadic International, Inc. recently announced the achievement of additional milestone payments in its collaborations with Proliant Health & Biologicals in life sciences and Inzymes ApS…
